CliniMACS® CD1c (BDCA-1) Product Line

The CD1c (BDCA-1) antigen belongs to the CD1 family and is involved in presentation of lipid antigens. In human blood, CD1c (BDCA-1) is exclusively expressed on CD11chigh CD123low myeloid dendritic cells and a small subpopulation of CD19+ B cells.1

Myeloid dendritic cells represent the major subset of dendritic cells in human peripheral blood (about 0.3% of white blood cells). They display a strong T cell stimulatory and cross-presenting capacity.2–4

The CliniMACS CD1c (BDCA-1)-Biotin Product Line consists of murine anti-CD1

... read more

Related products for CliniMACS® CD1c (BDCA-1) Product Line

Specifications for CliniMACS® CD1c (BDCA-1) Product Line
Overview

The CD1c (BDCA-1) antigen belongs to the CD1 family and is involved in presentation of lipid antigens. In human blood, CD1c (BDCA-1) is exclusively expressed on CD11chigh CD123low myeloid dendritic cells and a small subpopulation of CD19+ B cells.1

Myeloid dendritic cells represent the major subset of dendritic cells in human peripheral blood (about 0.3% of white blood cells). They display a strong T cell stimulatory and cross-presenting capacity.2–4

The CliniMACS CD1c (BDCA-1)-Biotin Product Line consists of murine anti-CD1c (BDCA-1) monoclonal antibodies conjugated to biotin.

One vial contains 5 mL sterile, non-pyrogenic solution.

The performance of the CliniMACS CD1c (BDCA-1)-Biotin Product Line depends on the individual separation strategy. For information on respective capacities, refer to the CliniMACS User Manual or contact your local representative.

Please inquire about required CliniMACS System components and accessories.

Detailed product information
Applications

The CliniMACS CD1c (BDCA-1)-Biotin Product Line was developed for the enrichment of CD1c (BDCA-1)+ myeloid dendritic cells from human heterogeneous hematologic cell populations in combination with the CliniMACS System.

After labeling of target cells with the CliniMACS CD1c (BDCA-1)-Biotin, the CliniMACS Anti-Biotin Reagent is used for the magnetic enrichment of CD1c (BDCA-1)+ cells from the cellular product. A CD19+ B cell depletion is recommended prior to the enrichment of CD1c (BDCA-1)+ cells, due to expression of CD1c (BDCA-1) on a subset of CD19+ B cells.

Referenced literature

CD1c (BDCA-1) enriched blood MDCs were used in clinical studies for the treatment of melanoma and prostate cancer.5,6

Disclaimer

The CliniMACS® System components, including Reagents, Tubing Sets, Instruments, and PBS/EDTA Buffer, are designed, manufactured and tested under a quality system certified to ISO 13485.

In the EU, the CliniMACS System components are available as CE-marked medical devices for their respective intended use, unless otherwise stated. The CliniMACS Reagents and Biotin Conjugates are intended for in vitro use only and are not designated for therapeutic use or direct infusion into patients. The CliniMACS Reagents in combination with the CliniMACS System are intended to separate human cells. Miltenyi Biotec as the manufacturer of the CliniMACS System does not give any recommendations regarding the use of separated cells for therapeutic purposes and does not make any claims regarding a clinical benefit. For the manufacturing and use of target cells in humans the national legislation and regulations - e.g., for the EU the Directive 2004/23/EC ("human tissues and cells"), or the Directive 2002/98/EC ("human blood and blood components") - must be followed. Thus, any clinical application of the target cells is exclusively within the responsibility of the user of a CliniMACS System.

In the US, the CliniMACS CD34 Reagent System, including the CliniMACS Plus Instrument, CliniMACS CD34 Reagent, CliniMACS Tubing Sets TS and LS, and the CliniMACS PBS/EDTA Buffer, is FDA approved as a Humanitarian Use Device (HUD), authorized by U.S. Federal law for use in the treatment of patients with acute myeloid leukemia (AML) in first complete remission. The effectiveness of the device for this indication has not been demonstrated. Other products of the CliniMACS Product Line are available for use only under an approved Investigational New Drug (IND) application, Investigational Device Exemption (IDE) or FDA approval.

CR/GMP products are for ex vivo cell processing only, and are not intended for human in vivo applications. CR/GMP products are designed, manufactured and tested under an ISO 13485 quality management system and are in compliance with relevant GMP guidelines. They are designed following the recommendations of USP <1043> on ancillary materials. The manufacturing and testing of CR/GMP products of biological origin are in compliance with EP chapter 5.2.12 for “Raw materials of biological origin for the production of cell-based and gene therapy medicinal products”.

Product data and images for CliniMACS® CD1c (BDCA-1) Product Line
Figure 1

Flow cytometric analysis of CD19-depleted cells (B) followed by the analysis of CD1c (BDCA-1)- enriched cells (C) using the CliniMACS CD19 System, CliniMACS CD1c (BDCA-1)-Biotin System and CliniMACS Anti-Biotin System in combination.

Flow cytometric analysis of CD1c (BDCA-1)+ cell enrichment
Resources for CliniMACS® CD1c (BDCA-1) Product Line
Documents and Protocols
Certificates

To access a Certificate of Analysis (CoA) follow the link below and enter the specific lot of your product.

Get certificate

Should you wish to request additional documentation, such as a Safety Data Sheet (SDS) in other languages than English or Swedish, an SDS-replacement document, or a Certificate of Origin (CoO), please direct your inquiry to your local technical support team.

Contact technical support

Citations for CliniMACS® CD1c (BDCA-1) Product Line
Publications
  1. Schnurr, M. et al. (2005) Tumor antigen processing and presentation depend critically on dendritic cell type and the mode of antigen delivery. Blood 105: 2465-2472
  2. Dzionek, A. et al. (2000) BDCA-2, BDCA-3, BDCA-4: Three markers for distinct subsets of dendritic cells in human peripheral blood. J Immunol 165: 6037-6046
  3. Kvale, E. et al. (2006) CD11c+ dendritic cells and plasmacytoid DCs are activated by human cytomegalovirus and retain efficient T cell-stimulatory capability upon infection. Blood 107: 2022-2029
  4. Prue et al. (2007) 5th Int. meeting on DC vaccination and other strategies to tip the balanced of the immune system (poster): P090
  5. Davis et al. (2005) 96th Annual Meeting of the AACR (poster): 3466
  6. Jefford, M. et al. (2003) Functional comparison of DCs generated in vivo with Flt3 ligand or in vitro from blood monocytes: differential regulation of function by specific classes of physiologic stimuli. Blood 102: 1753-1763

You have previously chosen International as your location.
What do you want to do?